PL3953393T3 - Połączenie farmaceutyczne antagonisty ep4 i inhibitorów punktów kontrolnych układu odpornościowego do leczenia nowotworów - Google Patents

Połączenie farmaceutyczne antagonisty ep4 i inhibitorów punktów kontrolnych układu odpornościowego do leczenia nowotworów

Info

Publication number
PL3953393T3
PL3953393T3 PL20730185.4T PL20730185T PL3953393T3 PL 3953393 T3 PL3953393 T3 PL 3953393T3 PL 20730185 T PL20730185 T PL 20730185T PL 3953393 T3 PL3953393 T3 PL 3953393T3
Authority
PL
Poland
Prior art keywords
tumours
antagonist
treatment
immune checkpoint
pharmaceutical combination
Prior art date
Application number
PL20730185.4T
Other languages
English (en)
Inventor
Lucio Claudio Rovati
Antonio Giordani
Filippo Magaraci
Gianfranco Caselli
Tiziana Piepoli
Daniele MAGGIONI
Albino BONAZZI
Original Assignee
Rottapharm Biotech S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Biotech S.R.L. filed Critical Rottapharm Biotech S.R.L.
Publication of PL3953393T3 publication Critical patent/PL3953393T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL20730185.4T 2019-04-09 2020-04-08 Połączenie farmaceutyczne antagonisty ep4 i inhibitorów punktów kontrolnych układu odpornościowego do leczenia nowotworów PL3953393T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19168253.3A EP3722319A1 (en) 2019-04-09 2019-04-09 Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours
PCT/EP2020/060054 WO2020208088A1 (en) 2019-04-09 2020-04-08 Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours

Publications (1)

Publication Number Publication Date
PL3953393T3 true PL3953393T3 (pl) 2023-04-17

Family

ID=66286074

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20730185.4T PL3953393T3 (pl) 2019-04-09 2020-04-08 Połączenie farmaceutyczne antagonisty ep4 i inhibitorów punktów kontrolnych układu odpornościowego do leczenia nowotworów

Country Status (12)

Country Link
US (2) US11590114B2 (pl)
EP (2) EP3722319A1 (pl)
JP (2) JP7671068B2 (pl)
KR (2) KR20260030953A (pl)
CN (2) CN113874043A (pl)
AU (1) AU2020273246B2 (pl)
BR (1) BR112021020107A2 (pl)
CA (2) CA3136164A1 (pl)
DK (1) DK3953393T3 (pl)
ES (1) ES2939490T3 (pl)
PL (1) PL3953393T3 (pl)
WO (1) WO2020208088A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722319A1 (en) * 2019-04-09 2020-10-14 Rottapharm Biotech S.r.l. Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours
WO2022257961A1 (zh) * 2021-06-08 2022-12-15 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物
CN119013017A (zh) * 2022-02-15 2024-11-22 治纳辅医药科技有限公司 包含抗癌剂和对前列腺素e2受体具有抑制活性的新化合物的用于治疗癌症的药物组合物
CN116251120A (zh) * 2023-01-30 2023-06-13 中国医学科学院基础医学研究所 含锂化合物在肿瘤治疗中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2679175C (en) 2007-02-26 2015-01-13 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
DK2729445T3 (en) 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
JP2014189462A (ja) * 2013-03-27 2014-10-06 Osaka Univ 結晶製造方法、準安定形結晶、医薬の製造方法および医薬
PT3482760T (pt) * 2016-07-07 2021-12-15 Ono Pharmaceutical Co Combinação compreendendo antagonista de ep4 e inibidor de ponto de verificação imunitário
US10342785B2 (en) * 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
JP7211358B2 (ja) * 2017-05-22 2023-01-24 小野薬品工業株式会社 Ｅｐ４アンタゴニスト
JP2021522211A (ja) * 2018-04-16 2021-08-30 アリーズ セラピューティクス， インコーポレイテッド Ｅｐ４阻害剤およびその使用
EP3722319A1 (en) * 2019-04-09 2020-10-14 Rottapharm Biotech S.r.l. Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours

Also Published As

Publication number Publication date
KR20210151137A (ko) 2021-12-13
US11590114B2 (en) 2023-02-28
JP7671068B2 (ja) 2025-05-01
CN113874043A (zh) 2021-12-31
KR20260030953A (ko) 2026-03-06
EP3953393B1 (en) 2022-12-14
CA3249304A1 (en) 2025-06-17
US20230122048A1 (en) 2023-04-20
CA3136164A1 (en) 2020-10-15
US20220142996A1 (en) 2022-05-12
JP7750570B2 (ja) 2025-10-07
JP2022527716A (ja) 2022-06-03
AU2020273246A1 (en) 2021-11-25
EP3953393A1 (en) 2022-02-16
WO2020208088A1 (en) 2020-10-15
JP2024156899A (ja) 2024-11-06
ES2939490T3 (es) 2023-04-24
AU2020273246B2 (en) 2022-12-01
KR102931586B1 (ko) 2026-02-26
EP3722319A1 (en) 2020-10-14
BR112021020107A2 (pt) 2021-12-07
US12544365B2 (en) 2026-02-10
CN120093746A (zh) 2025-06-06
DK3953393T3 (da) 2023-02-27

Similar Documents

Publication Publication Date Title
IL272948B1 (en) enpp1 inhibitors and their use for cancer treatment
IL282727A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
IL279347A (en) Gremlin-1 antagonist for cancer prevention and treatment
IL258212A (en) Combination therapy of bromodomain inhibitors and checkpoint blockade
ZA201900060B (en) Combination comprising ep4 antagonist and immune checkpoint inhibitor
EP3421039A4 (en) Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor
PL3953393T3 (pl) Połączenie farmaceutyczne antagonisty ep4 i inhibitorów punktów kontrolnych układu odpornościowego do leczenia nowotworów
IL245568A0 (en) Combination therapy includes an mdm2 inhibitor and one or more additional remotely active agents for the treatment of cancers
IL290123A (en) Combined treatment including antibodies against claudin 18.2 and immune checkpoint inhibitors for cancer treatment
MX2022006932A (es) Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
IL283598A (en) Combined treatment with radio-immune conjugates and a checkpoint inhibitor
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
IL261584A (en) Combination of cxcr4 antagonist and immune checkpoint inhibitor
IL282007A (en) Medicine to treat chronic cough
IL274198A (en) Use of Nox inhibitors to treat cancer
IL281357A (en) Cd73 inhibitors and their pharmacological uses
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
WO2017143115A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
EP4342544A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
IL267775A (en) Combined treatment with a Lantrin-1 interfering drug and immune checkpoint inhibitor drugs
IL290427A (en) Objects and methods for administering medical agents
IL291396A (en) mll1 inhibitors and anticancer drugs
HK40061608A (en) Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours
IL291196A (en) Standards and methods for determining the dose of the drug
IL286836A (en) Combinations of transcription inhibitors and immune checkpoint inhibitors to treat the disease